Alkem Laboratories Ltd share price logo

Alkem Share Price (ALKEM)

Check the latest share price of Alkem, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.

₹4847.50.02%

as on 04:01PM, 13 Jun 2025

NSE

bell
The current prices are delayed by 15 mins, login to check live prices.

Alkem Stock Performance

Get live Alkem share price, day's high and low, historical returns, and market stats.

  • Day's Low

    Day's High

    ₹4,743.5
    Day's Price Range
    ₹4,855
  • 52 Week's Low

    52 Week's High

    ₹4,491.65
    52-Week Price Range
    ₹6,439.9
1 Month Return-5.45 %
3 Month Return+ 0.61 %
1 Year Return-4.99 %
3 Year Return+ 57.76 %
5 Year Return+ 104.55 %
Previous Close₹4,846.50
Open₹4,805.00
Volume3.83L
Upper Circuit₹5,331.00
Lower Circuit₹4,362.00

Alkem Fundamentals & Key Indicators

Check Alkem market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

₹57,959.13 Cr

Return on Equity (ROE)

17.56

PE Ratio (TTM)

26.77

Return on capital employed (ROCE)

17.28

Industry PE ratio

57.39

Beta (LTM)

0.57

P/B Ratio

5.6

Dividend Yield

0.81

PEG Ratio

0.87

Quarterly Earnings Growth YOY

6.09

EPS (TTM)

151.52

Sector

Pharmaceuticals

Book Value

862.57

Technical Analysis

How to invest in Alkem?

Investing in Alkem is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Alkem or ALKEM on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

For example: You can buy 10 shares of Alkem or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Alkem with just a few clicks!

Alkem Stock's Interest Amongst Investors

117%

Period Jun 14, 2025 to May 15, 2025. Change in 30 Days vs previous period

Search interest for Alkem Laboratories Ltd Stock has increased by 117% in the last 30 days, reflecting an upward trend in search activity.

Alkem Valuation

Track how Alkem P/E has moved over time to understand its valuation trends.

Alkem in the last 5 years

  • Overview

  • Trends

Lowest (20.07x)

March 24, 2021

Today (26.77x)

June 13, 2025

Industry (57.39x)

June 13, 2025

Highest (44.21x)

August 9, 2023

LowHigh

Today’s Price to Earnings Ratio: 26.77x

Alkem Stock Recommendation

Get updated buy, sell, and hold recommendations by analysts on Alkem.

based on 21 analysts

HOLD

42.86%

Buy

19.05%

Hold

38.10%

Sell

42.86% of analysts recommend a 'HOLD' rating for Alkem. Average target price of ₹5187.81

Source: S&P Global Market Intelligence

Alkem Share Price Target

Get share price movements and forecasts by analysts on Alkem.

Alkem price forecast by 21 analysts

Upside of7.02%

High

₹6835

Target

₹5187.81

Low

₹4030

Alkem target price ₹5187.81, a slight upside of 7.02% compared to current price of ₹4847.5. According to 21 analysts rating.

Source: S&P Global Market Intelligence

Alkem Financial Results

Get the annual and quarterly financial summary of Alkem, including revenue, profit, loss and more.

Value in ₹ crore
DetailsQ4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25
Revenue

(in ₹ Cr)

2936 (0%)3032 (3%)3415 (13%)3374 (1%)3144 (7%)
Net Income

(in ₹ Cr)

304 (0%)550 (81%)702 (28%)641 (9%)323 (50%)
Net Profit Margin10.37% (0%)18.15% (75%)20.56% (13%)18.99% (8%)10.27% (46%)
Value in ₹ crore
DetailsFY21FY22FY23FY24
Total Assets

(in ₹ Cr)

10962 (0%)13369 (22%)12939 (3%)14291 (10%)
Total Liabilities

(in ₹ Cr)

3336 (0%)4625 (39%)3589 (22%)3737 (4%)
Value in ₹ crore
DetailsFY20FY21FY22FY23FY24
Operating Cash Flow

(in ₹ Cr)

682 (0%)1324 (94%)1299 (2%)1437 (11%)1687 (17%)

Indices Featuring Alkem Stock

Check stock indices that include Alkem.

NIFTY PHARMA

₹21,985.15

-0.23 (-51%)

S&P BSE 250 LargeMidCap

₹10,667.61

-0.59 (-63.82%)

Nifty Midcap 100

₹58,227.45

-0.37 (-213.4%)

BSE Mid-Cap

₹45,681.28

-0.32 (-145.76%)

BSE 200

₹11,252.01

-0.61 (-68.82%)

Nifty Midcap 50

₹16,391.90

-0.28 (-46.15%)

Nifty Midcap 150

₹21,433.05

-0.36 (-76.6%)

Nifty 200

₹13,825.40

-0.65 (-90.2%)

Nifty LargeMidcap 250

₹16,110.25

-0.53 (-85.2%)

Nifty 500

₹22,906.20

-0.61 (-140.25%)

Nifty Healthcare

₹14,328.65

0.04 (5.5%)

Nifty MidSmallcap 400

₹19,931.15

-0.37 (-73.35%)

S&P BSE 150 MidCap

₹15,914.77

-0.28 (-45.29%)

S&P BSE 400 MidSmallCap

₹12,015.06

-0.31 (-37.67%)

BSE Healthcare

₹43,995.31

0.08 (34.42%)

BSE 500

₹35,946.69

-0.57 (-206.81%)

Alkem Earnings and Dividends

View detailed summary of the earnings and dividend history of Alkem.

  • Alkem Laboratories Ltd Earnings Results

    Alkem Laboratories Ltd’s net profit jumped 4.19% since last year same period to ₹305.86Cr in the Q4 2024-2025. On a quarterly growth basis, Alkem Laboratories Ltd has generated -51.13% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Alkem Laboratories Ltd Dividends February,2025

    In the quarter ending December 2024, Alkem Laboratories Ltd has declared dividend of ₹37 - translating a dividend yield of 1.59%.

    Read More about Dividends

Alkem Shareholding Pattern

View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Alkem.

InvestorsHoldings %Quarterly Trend3M change
Promoter Holdings
55.13%
0.00
Foreign Institutions
9.41%
0.00
Mutual Funds
14.97%
0.00
Retail Investors
16.05%
0.00
Others
4.45%
0.00

Alkem vs Peers

Compare market cap, revenue, PE, and other key metrics of Alkem with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
HOLD57,959.1320.91%0.561,81112,667
HOLD24,742.2617.16%0.534922,461
HOLD35,946.57111.13%0.693545,553
BUY9,759.3810.65%0.64119547
BUY5,413.2819.47%0.5469571

Alkem News & Key Events

Latest news and events in one place to help you make informed investing decisions in Alkem.

  • Alkem Laboratories Declares 400% Final Dividend - 14 Jun, 2025

    Alkem Laboratories Ltd announced a 400% final dividend of Rs 8 per share for FY25, with a record date set for August 8, 2025. The company reported a 6% increase in net profit to Rs 322 crore for Q4 FY25, driven by strong domestic growth. Revenue for FY25 rose to Rs 12,964 crore from Rs 12,667 crore in FY24.
  • Alkem Labs Files Trademark Infringement Suit - 13 Jun, 2025

    Alkem Laboratories has filed a lawsuit against an IPO-bound company for trademark infringement regarding the name 'Allchem.' The company seeks a permanent injunction and damages of ₹2 crore.
  • Alkem Laboratories Reports Decline in Financial Performance - 12 Jun, 2025

    Alkem Laboratories reported a 13.55% decline in net sales to Rs 2,044.94 crore for March 2025, with net profit down 14.78% to Rs 276.94 crore. EBITDA also fell by 16.88%. The stock has seen negative returns of -11.01% over the last six months.
  • Alkem Laboratories Sees Third Straight Session Gain - 10 Jun, 2025

    Alkem Laboratories Ltd is up 2.08% today, marking its third consecutive session of gains. However, the stock is down 1.81% over the past year, underperforming both the NIFTY and Nifty Pharma index. The stock's PE ratio stands at 27.89 based on TTM earnings.
  • Stake Sale and Ratings Update for Alkem Laboratories - 04 Jun, 2025

    Alkem Laboratories faced notable events, including a stake sale by Jayanti Sinha, a large block deal, and an updated target price from I-Sec.
  • Alkem Promoter to Offload Stake via Block Deal - 03 Jun, 2025

    Jayanti Sinha, a promoter of Alkem Laboratories, plans to sell a 1.42% stake through a block deal worth ₹825 crore at a floor price of ₹4,850 per share, reflecting a 3% discount. Alkem's recent financial results showed a year-on-year profit rise but fell short of estimates, impacting stock performance.
  • Alkem Reports Mixed Q4 Results Amid Analyst Downgrades - 30 May, 2025

    Alkem Laboratories reported a 6% rise in Q4 net profit to Rs 322 crore, but Jefferies downgraded the stock due to margin concerns. Nomura maintained a Buy rating, anticipating growth from the upcoming Semaglutide launch despite mixed guidance for FY26.
  • Alkem Laboratories Reports Q4 Results, Misses Estimates - 29 May, 2025

    Alkem Laboratories announced a 4% increase in Q4 net profit to ₹306 crore, falling short of market expectations. Revenue and EBITDA also missed estimates, despite growth in the India business and non-US markets. The company declared an ₹8 dividend.

Insights on Alkem Laboratories Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 14.01% to 14.97% in Mar 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 131.1% return, outperforming this stock by 73.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 45.3% return, outperforming this stock by 50.3%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 3.54K Cr → 3.28K Cr (in ₹), with an average decrease of 3.7% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 688.64 Cr → 305.86 Cr (in ₹), with an average decrease of 30.1% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, ALKEM stock has moved down by -5.5%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 16.18% to 16.05% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 10.15% to 9.41% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 55.66% to 55.13% in Mar 2025 quarter

About Alkem

Alkem Laboratories Ltd is a leading pharmaceutical company founded in 1973 by Mr. Samir C. Desai.

With its headquarters in Mumbai, India, Alkem Laboratories is engaged in the manufacture of a wide range of pharmaceutical products across multiple therapeutic categories, including cardiovascular, central nervous system, gastro-intestinal, anti-infective, diabetology, and nutrition. The company has a strong presence in the Indian market and exports its products to over 50 countries.

Revenue: ₹3,143.75Cr as on March 2025 (Q4 FY25)
Net Profit: ₹323.01Cr as on March 2025 (Q4 FY25)
Listing date: 23 Dec, 2015
Chairperson Name: Basudeo N Singh
OrganisationAlkem Laboratories Ltd
HeadquartersMumbai
IndustryPharmaceuticals
CEOBasudeo N Singh
E-voting on sharesClick here to vote

FAQs

What is Alkem share price today?

Alkem share price today stands at ₹4847.5, Open: ₹4805, Previous Close: ₹4846.5, High: ₹4855, Low: ₹4743.5, 52 Week High: ₹6439.9, 52 Week Low: ₹4491.65.

What is today's traded volume of Alkem?

Today's traded volume of Alkem is 3.83L. Which means that 3.83L shares of Alkem were bought and sold on the stock market during today's trading session.

What is Alkem's market cap today?

Today's market capitalisation of Alkem is ₹57,959.13 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.

What is the 52 week high and 52 week low range of Alkem?

Alkem’s 52 week high is ₹6439.9 and 52 week low is ₹4491.65. The current share price of Alkem is ₹4847.5, which is -24.73% down from its 52 week high and 7.92% up from its 52 week low.